Seoul Pharma Co., Ltd (KOSDAQ:018680)
1,870.00
-2.00 (-0.11%)
At close: Oct 23, 2026
Seoul Pharma Revenue
Seoul Pharma had revenue of 11.76B KRW in the quarter ending June 30, 2026, a decrease of -2.07%. This brings the company's total for the last twelve months to 51.08B, down -2.14% year-over-year. In the year 2025, Seoul Pharma had annual revenue of 52.15B, down -2.67%. That makes Seoul Pharma the 29,731st largest company in the world by revenue and 1,852nd in South Korea.
Revenue (ttm)
51.08B
Revenue Growth
-2.14%
P/S Ratio
0.43
Revenue / Employee
296.96M
Employees
172
Market Cap
21.80B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 52.15B | -1.43B | -2.67% |
| Dec 31, 2024 | 53.58B | 1.12B | 2.14% |
| Dec 31, 2023 | 52.46B | 2.40B | 4.80% |
| Dec 31, 2022 | 50.06B | 9.59B | 23.71% |
| Dec 31, 2021 | 40.46B | -11.77B | -22.53% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Korea Arlico Pharm | 195.70B |
| Hurum | 94.89B |
| Korean Drug | 65.39B |
| WooGene B&G | 56.49B |
| Kwangdong Healthbio | 38.10B |
| Union Korea Pharm | 25.45B |
| Daesung Microbiological Labs. | 25.20B |
| BIFIDO | 14.63B |